Wolf Haldenstein Announces Securities Class Action Lawsuit Against Zynex, Inc.
On March 31, 2025, Wolf Haldenstein Adler Freeman & Herz LLP, a national law firm renowned for its representation of investors, announced the filing of a securities class action lawsuit against Zynex, Inc. (NASDAQ: ZYXI) on behalf of all persons or entities who purchased or otherwise acquired the common stocks of Zynex between March 13, 2023, and March 11, 2025, inclusive (the “Class Period”).
Background on Zynex, Inc.
Zynex, Inc. is a Colorado-based healthcare technology company that designs, manufactures, and markets medical devices and related services. The company’s products include electrotherapy devices, transcutaneous electrical nerve stimulation (TENS) devices, and functional electrical stimulation (FES) systems for physical therapy and pain management. Zynex’s common stock is traded on the NASDAQ Stock Market under the ticker symbol “ZYXI.”
Allegations in the Securities Class Action Lawsuit
The complaint alleges that during the Class Period, Zynex made false and misleading statements regarding its business, operational, and financial metrics. Specifically, defendants failed to disclose: (1) that the company’s revenue growth was not sustainable due to a lack of product innovation and increasing competition; (2) that Zynex was experiencing significant declines in sales of certain product lines, including its Transcutaneous Spinal Stimulation Systems (TS3P and TS4); and (3) that the company’s financial statements contained material misstatements and omissions.
Impact on Individual Investors
If you purchased or otherwise acquired the common stocks of Zynex, Inc. during the Class Period and suffered a loss as a result, you may be entitled to compensation. The lawsuit seeks to recover damages on behalf of the Class members, including their net loss from the purchase of Zynex common stock and/or the rental or sale of securities during the Class Period. To be eligible for inclusion in the Class, you must have purchased Zynex common stock during the Class Period and must not have sold your shares prior to March 11, 2025.
Impact on the World
The securities class action lawsuit against Zynex, Inc. could have far-reaching consequences for the healthcare technology industry as a whole. If the allegations are proven true, investors may become more cautious when considering investments in similar companies, leading to increased scrutiny and potential regulatory action. Furthermore, the lawsuit could deter other companies from making similar misrepresentations in the future, promoting greater transparency and honesty in corporate reporting.
Conclusion
The filing of a securities class action lawsuit against Zynex, Inc. by Wolf Haldenstein Adler Freeman & Herz LLP is a significant development for investors who purchased the company’s common stock during the Class Period. The allegations, if proven true, could result in substantial damages for affected investors. Moreover, the lawsuit’s potential impact on the healthcare technology industry and corporate reporting practices underscores the importance of transparency and honesty in business dealings.
- If you purchased Zynex common stock between March 13, 2023, and March 11, 2025, you may be eligible to join the securities class action lawsuit.
- The lawsuit alleges that Zynex made false and misleading statements regarding its business, operational, and financial metrics during the Class Period.
- If the allegations are proven true, investors may be entitled to compensation for their losses.
- The lawsuit could have far-reaching consequences for the healthcare technology industry and corporate reporting practices.
